News
Moderna's Q1 revenues rocket, thanks to ex-US sales
Moderna saw its Q1 sales nearly triple to $389m, almost a threefold rise on the same period of 2025, with international markets driving the increase.
News
Axsome breaks new ground in Alzheimer's with Auvelity OK
Axsome's Auvelity has become the first non-antipsychotic therapy for agitation in patients with Alzheimer's disease to be approved by the FDA.
News
GLP-1s drive Lilly's Q1, but it's reticent on oral launch
Investors are itching for news on the rollout of Lilly's oral weight-loss drug Foundayo, but there's little information in its first-quarter update.
News
Norgine gets first EU approval for WHIM syndrome therapy
Patients in the EU with the ultra-rare disease WHIM syndrome now have their first approved treatment, Norgine's Xolremdi.
News
Chiesi signs $1.9bn deal to buy KalVista and its HAE drug
Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
News
Press Releases
Views & Analysis
Editor's Picks
Editor's Picks
